Logo image
Back
Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa
Journal article   Peer reviewed

Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa

Christine Tagliaferri Rael, Doyel Das, Rebecca Giguere, Jonathan Porter, Ewa Bryndza Tfaily, Camagu Tuswa Haynes, Titcha Ho, Stacey McKenna, Javier Lopez-Ríos, Cody Lentz, …
AIDS research and human retroviruses, Forthcoming
24 Aug 2026
DOI: https://doi.org/10.1177/08892229261480775
PMID: 42638181

Abstract

disparities in HIV HIV in men who have sex with men pre-exposure prophylaxis (PrEP)
Several forms of HIV pre-exposure prophylaxis (PrEP) are approved, prescribed off-label, or in development in the United States, including daily oral tablets, long-acting injectable cabotegravir (CAB-LA), removable implants, and rectal tenofovir products. To understand how health care providers prioritize among these options, 30 providers from the United States, Thailand, and South Africa completed online surveys, and 10 participated in in-depth interviews. Providers shared their perspectives on current and emerging PrEP products, key informational needs for gay and bisexual men, and preferred educational strategies. When asked to rank PrEP options if all were simultaneously available, providers most often prioritized removable implants ( = 3), daily oral PrEP ( = 3), CAB-LA ( = 1), and rectal douches/enemas ( = 1), while others ( = 2) emphasized patient preference. Overall, providers noted that each product has unique advantages and expressed support for digital shared decision-making tools to enhance patient-provider communication about PrEP selection.

Metrics

1 Record Views

Details

Logo image